Catheter Precision Inc. (NYSE:VTAK) shares are trending on Wednesday.
Shares of the Carolina-based medical device and technology company jumped 26.62% to $0.90 in after-hours trading on Tuesday, after Catheter Precision announced Flyte, its regional air mobility unit, will equip its Cirrus Vision Jet fleet with LifeVac‘s airway-clearance devices.
Why It Matters for Investors
LifeVac developed the first Food and Drug Administration-authorized non-powered device designed to help clear a blocked airway during choking emergencies. The device has been used in thousands of reported choking incidents around the world. It is used by families, schools, healthcare facilities, first responders and other organizations that want to be better prepared for choking emergencies.
According to the company, the LifeVac deal extends the fleet’s safety systems from flight-deck technology into cabin medical preparedness, reinforcing Flyte’s standardized, single-aircraft-type strategy.
Marc Sellouk, Founder of Flyte, said, “Safety isn’t one feature. It’s a system, and it’s our foundation. We chose the Vision Jet, standardized our fleet, and built our training, maintenance and procedures around it for one reason: to protect the people onboard.”
Arthur Lih, Founder and CEO of LifeVac, said, “Choking emergencies happen fast and when you are in the air, there is no one to call. By pairing LifeVac’s life-saving airway clearance technology with the Vision Jet’s industry-leading safety systems, we’re helping create one of the most comprehensive safety platforms in the skies.”
Patents Add Fuel
A day earlier, Catheter Precision announced two new patents. One patent covers its VIVO ventricular tachycardia mapping platform, while the other is related to its Cardionomix heart failure portfolio.
Trading Metrics, Technical Analysis
Catheter has a market capitalization of $1.91 million, with a 52-week high of $4.94 and a 52-week low of $0.61.
Volume rose to 21.69 million shares, more than three times the average daily volume of 6.23 million, indicating elevated trading activity and increased investor interest.
The Relative Strength Index (RSI) of VTAK stands at 36.21.
Over the past 12 months, the stock has dropped 84.64%.
VTAK is currently positioned close to its annual low.
Price Action: According to Benzinga Pro data, the stock closed the regular session at $0.71, down 6.98%.
Benzinga’s Edge Stock Rankings indicate that VTAK has a negative price trend across all time frames.
Photo Courtesy: prassarp on Shutterstock.com
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Login to comment